ANASTROZOLE Drug Patent Profile
✉ Email this page to a colleague
When do Anastrozole patents expire, and when can generic versions of Anastrozole launch?
Anastrozole is a drug marketed by Accord Hlthcare, Apotex Inc, Beijing Yiling, Chartwell Molecular, Chartwell Rx, Cipla, Eugia Pharma, Fresenius Kabi Usa, Hikma, Impax Labs Inc, Kenton, Natco Pharma Ltd, Norvium Bioscience, Sandoz, Sun Pharm Inds Ltd, Synthon Pharms, Teva Pharms, Watson Labs Teva, and Zydus Pharms Usa Inc. and is included in nineteen NDAs.
The generic ingredient in ANASTROZOLE is anastrozole. There are twenty-four drug master file entries for this compound. Twenty-four suppliers are listed for this compound. Additional details are available on the anastrozole profile page.
DrugPatentWatch® Litigation and Generic Entry Outlook for Anastrozole
A generic version of ANASTROZOLE was approved as anastrozole by ACCORD HLTHCARE on June 28th, 2010.
AI Research Assistant
Questions you can ask:
- What is the 5 year forecast for ANASTROZOLE?
- What are the global sales for ANASTROZOLE?
- What is Average Wholesale Price for ANASTROZOLE?
Summary for ANASTROZOLE
US Patents: | 0 |
Applicants: | 19 |
NDAs: | 19 |
Finished Product Suppliers / Packagers: | 23 |
Raw Ingredient (Bulk) Api Vendors: | 119 |
Clinical Trials: | 316 |
Drug Prices: | Drug price information for ANASTROZOLE |
Drug Sales Revenues: | Drug sales revenues for ANASTROZOLE |
DailyMed Link: | ANASTROZOLE at DailyMed |
Recent Clinical Trials for ANASTROZOLE
Identify potential brand extensions & 505(b)(2) entrants
Sponsor | Phase |
---|---|
Breast Cancer Research Foundation | Phase 2 |
University of Wisconsin, Madison | Phase 2 |
Verastem, Inc. | Phase 3 |
Pharmacology for ANASTROZOLE
Drug Class | Aromatase Inhibitor |
Mechanism of Action | Aromatase Inhibitors |